	Term	observed
1	Aphasia (HP:0002381)	$\checkmark$
2	Slurred speech (HP:0001350)	$\checkmark$
3	Agnosia (HP:0010524)	$\checkmark$
4	Confusion (HP:0001289)	$\checkmark$
5	Encephalopathy (HP:0001298)	$\checkmark$
6	Headache (HP:0002315)	$\checkmark$
7	Migraine (HP:0002076)	$\checkmark$
8	Anosmia (HP:0000458)	$\checkmark$
9	Parageusia (HP:0031249)	$\checkmark$
10	Depression (HP:0000716)	$\checkmark$
11	Memory impairment (HP:0002354)	$\checkmark$
12	Attention deficit hyperactivity disorder (HP:000701	
13	Auditory hallucinations (HP:0008765)	$\checkmark$
14	Hallucinations (HP:0000738)	$\checkmark$
15	Visual hallucinations (HP:0002367)	$\checkmark$
16	Abnormal reflex (HP:0031826)	$\checkmark$
17	Abnormality of movement (HP:0100022)	$\checkmark$
18	Ataxia (HP:0001251)	$\checkmark$
19	Dysarthria (HP:0001260)	$\checkmark$
20	Dysphagia (HP:0002015)	$\checkmark$
<b>2</b> 1	Dystonia (HP:0001332)	$\checkmark$
22	Hyperesthesia (HP:0100963)	$\checkmark$
23	Hyperkinetic movements (HP:0002487)	<b>↓</b>
20 24	Muscle weakness (HP:0001324)	<b>↓</b>
25	Orthostatic hypotension (HP:0001278)	$\checkmark$
26 26	Paresthesia (HP:0003401)	$\checkmark$
20 27	Polyneuropathy (HP:0001271)	• •
28	Seizure (HP:0001250)	<b>v</b>
20 29	Skeletal muscle atrophy (HP:0003202)	<b>v</b>
$\frac{29}{30}$	Somatic sensory dysfunction (HP:0003474)	$\checkmark$
31	Tremor (HP:0001337)	↓ √
32	Insomnia (HP:0100785)	▼ .(
33	Restless legs (HP:0012452)	V
34	Sleep apnea (HP:0010535)	V
35	Anomic aphasia (HP:0030784)	v
36	Bilingual aphasia (HP:0033849)	-
30 37	Expressive aphasia (HP:0002427)	-
38	Receptive aphasia (HP:0033848)	-
39		-
	Bradykinesia (HP:0002067) Bradymbronia (HP:0031843)	-
40 41	Bradyphrenia (HP:0031843) Cognitive impairment (HP:0100542)	-
41 42	Cognitive impairment (HP:0100543) Diminished ability to concentrate (HP:0021087)	-
42	Diminished ability to concentrate (HP:0031987)	-
43	Tachyphrenia (HP:0033844)	-
44 45	Ageusia (HP:0041051)	-
45 46	Hypogeusia (HP:0000224)	-
46	Hyposmia (HP:0004409)	- ied on next page

Table S1. Neuropsychiatric HPO terms that were observed ( $\checkmark$ ) or not (-) in the EHR data.

Table S1 – continued from previous page				
	Term	observed?		
47	Phantageusia (HP:0033847)	-		
48	Phantosmia (HP:0033693)	-		
49	Aggressive behavior (HP:0000718)	-		
50	Dysphoria (HP:0033838)	-		
51	Emotional lability (HP:0000712)	-		
52	Euphoria (HP:0031844)	-		
53	Mania (HP:0100754)	-		
54	Sense of impending doom (HP:0033845)	-		
55	Suicidal ideation (HP:0031589)	-		
56	Tearfulness (HP:0033705)	-		
57	Anterograde memory impairment (HP:0033689)	-		
58	Long term memory impairment (HP:0033688)	_		
59	Procedural memory loss (HP:0033691)	-		
60	Short term memory impairment (HP:0033687)	-		
61	Anxiety (HP:0000739)	-		
62	Apathy (HP:0000741)	_		
63	Brain fog (HP:0033630)	_		
64	Delusions (HP:0000746)	_		
65	Impaired executive functioning (HP:0033051)	_		
66	Impulsivity (HP:0100710)	_		
67	Irritability (HP:0000737)	-		
68	Panic attack (HP:0025269)	-		
69	Phonophobia (HP:0002183)	-		
	Polydipsia (HP:0001959)	-		
70 71	· - · · /	-		
71 79	Posttraumatic stress symptom (HP:0033676)	-		
72 72	Short attention span (HP:0000736)	-		
73	Tactile hallucination (HP:0033694)	-		
74 75	Abnormal exteroceptive sensation (HP:0033747)	-		
75	Babinski sign (HP:0003487)	-		
76	Dysmetria (HP:0001310) $\Box$	-		
77	Facial paralysis (HP:0007209)	-		
78	Frontal release signs (HP:0000743)	-		
79	Gait disturbance (HP:0001288)	-		
80	Hand muscle weakness (HP:0030237)	-		
81	Hypoesthesia (HP:0033748)	-		
82	Hypotonia (HP:0001252)	-		
83	Muscle spasm (HP:0003394)	-		
84	Parkinsonism (HP:0001300)	-		
85	Rigidity (HP:0002063)	-		
86	Spasticity (HP:0001257)	-		
87	Unilateral facial palsy (HP:0012799)	-		
88	Maintenance insomnia (HP:0031355)	-		
89	Sleep disturbance (HP:0002360)	-		
90	Sleep onset insomnia (HP:0031354)	-		
91	Terminal insomnia (HP:0031356)	-		

Table S1 – continued from previous page

	Term	observed?
92	Nasal congestion (HP:0001742)	$\checkmark$
93	Pharyngalgia (HP:0033050)	$\checkmark$
94	Ear pain (HP:0030766)	$\checkmark$
95	Hearing impairment (HP:0000365)	$\checkmark$
96	Hyperacusis (HP:0010780)	$\checkmark$
97	Tinnitus (HP:0000360)	$\checkmark$
98	Vertigo (HP:0002321)	$\checkmark$
99	Dysphonia (HP:0001618)	-
100	Rhinitis (HP:0012384)	-
101	Pulsatile tinnitus (HP:0008629)	-

Table S2. ENT HPO terms that were observed (  $\checkmark$  ) or not (-) in the EHR data.

	Term	observed?
102	Dermatographic urticaria (HP:0011971)	$\checkmark$
103	Skin rash (HP:0000988)	$\checkmark$
104	Alopecia (HP:0001596)	-
105	Flushing (HP:0031284)	-
106	Fragile nails (HP:0001808)	-
107	Hyperhidrosis (HP:0000975)	-
108	Petechiae (HP:0000967)	-
109	Pruritus (HP:0000989)	-
110	Pseudo-chilblain (HP:0033696)	-
111	Scaling skin (HP:0040189)	-

Table S3. Skin HPO terms that were observed (  $\checkmark$  ) or not (-) in the EHR data.

	Term	observed?
112	Atelectasis (HP:0100750)	$\checkmark$
113	Bronchiectasis (HP:0002110)	$\checkmark$
114	Pulmonary fibrosis (HP:0002206)	$\checkmark$
115	Hypoxemia (HP:0012418)	$\checkmark$
116	Pleuritis (HP:0002102)	$\checkmark$
117	Pulmonary embolism (HP:0002204)	$\checkmark$
118	Cough (HP:0012735)	$\checkmark$
119	Dyspnea (HP:0002094)	$\checkmark$
120	Hemoptysis (HP:0002105)	$\checkmark$
121	Sneeze (HP:0025095)	$\checkmark$
122	Wheezing (HP:0030828)	$\checkmark$
123	Abnormal pulmonary thoracic imaging finding (HP:0031983)	-
124	Centrilobular ground-glass opacification on pulmonary HRCT (HP:0025180)	-
125	Crazy-paving pattern (HP:0033659)	-
126	Interlobular septal thickening (HP:0030879)	-
127	Parenchymal consolidation (HP:0032177)	-
128	Pleural thickening (HP:0031944)	-
129	Pulmonary bulla (HP:0032446)	-
130	Pulmonary interstitial thickening (HP:0033711)	-
131	Reticular pattern on pulmonary HRCT (HP:0025390)	-
132	Solid pulmonary nodule (HP:0033609)	-
133	Subsolid pulmonary nodule (HP:0033610)	-
134	Subpleural curvilinear line (HP:0033702)	-
135	Airway obstruction (HP:0006536)	_
136	Decreased DLCO (HP:0045051)	-
137	Decreased maximal oxygen uptake (HP:0033760)	-
138	Decreased RV/TLC ratio (HP:0033773)	-
139	Ground-glass opacification (HP:0025179)	-
140	Oxygen desaturation on exertion (HP:0030874)	-
141	Reduced FEV1/FVC ratio (HP:0030877)	-
142	Reduced forced expiratory volume in one second (HP:0032342)	-
143	Reduced forced vital capacity (HP:0032341)	_
144	Reduced functional residual capacity (HP:0033750)	-
145	Reduced residual volume (HP:0033753)	_
146	Reduced total lung capacity (HP:0033169)	_
147	Restrictive ventilatory defect (HP:0002091)	-
148	Exertional dyspnea (HP:0002875)	_
149	Increased sputum production (HP:0033709)	_
150	Nonproductive cough (HP:0031246)	-
151	Pleuritic chest pain (HP:0033771)	_
152	Productive cough (HP:0031245)	_
153	Rest dyspnea (HP:0033710)	_
154	Rhinorrhea (HP:0031417)	_
$151 \\ 155$	Rhonchi (HP:0030831)	_
156	Tachypnea (HP:0002789)	_

Table S4.	Pulmonary	HPO	$\operatorname{terms}$	that	were	observed	l (√	í) o	r not	(-) i	n the	EHR	data.

	Term	observed?
157	Diabetes mellitus (HP:0000819)	$\checkmark$
158	Edema (HP:0000969)	$\checkmark$
159	Fever $(HP:0001945)$	$\checkmark$
160	Hypothermia (HP:0002045)	$\checkmark$
161	Irregular menstruation (HP:0000858)	$\checkmark$
162	Menorrhagia (HP:0000132)	$\checkmark$
163	Renal insufficiency (HP:0000083)	$\checkmark$
164	Urinary incontinence (HP:0000020)	$\checkmark$
165	Decreased glomerular filtration rate (HP:0012213)	-
166	Female sexual dysfunction (HP:0030014)	-
167	Heat intolerance (HP:0002046)	-
168	Low-grade fever (HP:0011134)	-
169	Male sexual dysfunction (HP:0040307)	-
170	Pancreatitis (HP:0001733)	-
171	Postmenopausal bleeding (HP:0033840)	-
172	Recurrent fever (HP:0001954)	-
173	Temperature instability (HP:0005968)	-
174	Testicular pain (HP:0033839)	-

Table S5. Endocrine HPO terms that were observed (  $\checkmark$  ) or not (-) in the EHR data.

Table S6. Immunology HPO terms that were observed ( $\checkmark$ ) or not (-) in the EHR data.

	Term	observed?
175	Anaphylactic shock (HP:0100845)	$\checkmark$
176	Lymphadenopathy (HP:0002716)	$\checkmark$
177	Lymphopenia (HP:0001888)	$\checkmark$
178	Antinuclear antibody positivity (HP:0003493)	-
179	Anti-thyroid peroxidase antibody positivity (HP:0025379)	-
180	Anti-thyroglobulin antibody positivity (HP:0032069)	-

	Term	observed?
181	Arthritis (HP:0001369)	$\checkmark$
182	Asthenia (HP:0025406)	$\checkmark$
183	Difficulty walking (HP:0002355)	$\checkmark$
184	Fatigue (HP:0012378)	$\checkmark$
185	Shivering (HP:0025144)	$\checkmark$
186	Xerostomia (HP:0000217)	$\checkmark$
187	Arthralgia (HP:0002829)	$\checkmark$
188	Chest pain $(HP:0100749)$	$\checkmark$
189	Limb pain (HP:0009763)	$\checkmark$
190	Myalgia (HP:0003326)	$\checkmark$
191	Pain (HP:0012531)	$\checkmark$
192	Chest tightness (HP:0031352)	-
193	Chills (HP:0025143)	-
194	Coldness (HP:0033850)	-
195	Diminished health-related quality of life (HP:0033665)	-
196	Diminished mental health (HP:0033667)	-
197	Diminished physical functioning (HP:0033666)	-
198	Exercise intolerance (HP:0003546)	-
199	Frailty (HP:0033675)	-
200	Impaired ability to bathe oneself $(HP:0031059)$	-
201	Impaired ability to dress oneself (HP:0031060)	-
202	Impairment of activities of daily living (HP:0031058)	-
203	Malaise $(HP:0033834)$	-
204	Night sweats (HP:0030166)	-
205	Occupational disability (HP:0033695)	-
206	Postexertional malaise (HP:0030973)	-
207	Stiff neck (HP:0025258)	-
208	Weight loss (HP:0001824)	-
209	Body ache (HP:0033047)	-
210	Bone pain (HP:0002653)	-
211	Intrascapular pain (HP:0033746)	-
212	Neuralgia (HP:0033345)	-

<b>Table S7. General</b> HPO terms that were observed ( $\checkmark$ ) or not (-) in the EHR data.	
--	--

	Term	observed?
213	Bradycardia (HP:0001662)	$\checkmark$
214	Hypotension (HP:0002615)	$\checkmark$
215	Myocarditis (HP:0012819)	$\checkmark$
216	Tachycardia (HP:0001649)	$\checkmark$
217	Angina pectoris (HP:0001681)	$\checkmark$
218	Palpitations (HP:0001962)	$\checkmark$
219	Elevated myocardial native T1 (HP:4000006)	-
220	Elevated myocardial native T2 (HP:4000003)	-
221	Hypertension (HP:0000822)	-
222	Increased circulating troponin T concentration (HP:0410174)	-
223	Increased circulating troponin I concentration (HP:0410173)	-
224	Increased heart rate variability (HP:0031862)	-
225	Increased left ventricular end-diastolic volume (HP:0033755)	-
226	Myocardial late gadolinium enhancement (HP:4000004)	-
227	Pericardial effusion (HP:0001698)	-
228	Pericardial late gadolinium enhancement (HP:4000005)	-
229	Reduced ejection fraction (HP:0012664)	-
230	Venous thrombosis (HP:0004936)	-
231	Stroke (HP:0001297)	-
232	Syncope (HP:0001279)	_

Table S8. Cardiovascular HPO terms that were observed ( $\checkmark$ ) or not (-) in the EHR data.

	Term	observed?
233	Gastroesophageal reflux (HP:0002020)	$\checkmark$
234	Gastroparesis (HP:0002578)	$\checkmark$
235	Hepatic steatosis (HP:0001397)	$\checkmark$
236	Hepatomegaly (HP:0002240)	$\checkmark$
237	Hepatitis (HP:0012115)	$\checkmark$
238	Malnutrition (HP:0004395)	$\checkmark$
239	Splenomegaly (HP:0001744)	$\checkmark$
240	Abdominal pain (HP:0002027)	$\checkmark$
241	Bowel incontinence (HP:0002607)	$\checkmark$
242	Constipation (HP:0002019)	$\checkmark$
243	Diarrhea (HP:0002014)	$\checkmark$
244	Nausea (HP:0002018)	$\checkmark$
245	Vomiting (HP:0002013)	$\checkmark$
246	Gastric ulcer (HP:0002592)	-
247	Pancreatic steatosis (HP:0033757)	-
248	Abdominal symptom (HP:0011458)	-
249	Anorexia (HP:0002039)	-
250	Early satiety (HP:0033842)	-
251	Poor appetite (HP:0004396)	_

Table S9. Gastrointestinal HPO terms that were observed (  $\checkmark$  ) or not (-) in the EHR data.

Table S10. Laboratory HPO terms that were observed (  $\checkmark$  ) or not (-) in the EHR data.

	Term	observed?
252	Decreased circulating calcifediol concentration (HP:0012053)	$\checkmark$
253	Elevated circulating alkaline phosphatase concentration (HP:0003155)	$\checkmark$
254	Elevated circulating alanine aminotransferase concentration (HP:0031964)	$\checkmark$
255	Elevated circulating aspartate aminotransferase concentration (HP:0031956)	$\checkmark$
256	Elevated circulating creatinine concentration (HP:0003259)	$\checkmark$
257	Elevated circulating creatine kinase concentration (HP:0003236)	$\checkmark$
258	Elevated circulating thyroid-stimulating hormone concentration (HP:0002925)	$\checkmark$
259	Elevated erythrocyte sedimentation rate (HP:0003565)	$\checkmark$
260	Elevated gamma-glutamyltransferase level (HP:0030948)	$\checkmark$
261	Hypocalcemia (HP:0002901)	$\checkmark$
262	Hypofibrinogenemia (HP:0011900)	$\checkmark$
263	Hyperglycemia (HP:0003074)	$\checkmark$
264	Hypoglycemia (HP:0001943)	$\checkmark$
265	Hypophosphatemia (HP:0002148)	$\checkmark$
266	Increased circulating ferritin concentration (HP:0003281)	$\checkmark$
267	Thrombocytopenia (HP:0001873)	$\checkmark$
268	Elevated circulating C-reactive protein concentration (HP:0011227)	-
269	Elevated circulating D-dimer concentration (HP:0033106)	-
270	Elevated circulating soluble CD25 concentration (HP:0033833)	-
271	Increased circulating interleukin 6 (HP:0030783)	-
272	Increased circulating lactate dehydrogenase concentration $(HP:0025435)$	-
273	Increased circulating NT-proBNP concentration (HP:0031185)	-
274	Increased circulating procalcitonin concentration (HP:0032308)	-

	Term	observed?
275	Conjunctivitis (HP:0000509)	$\checkmark$
276	Diplopia (HP:0000651)	$\checkmark$
277	Keratoconjunctivitis sicca (HP:0001097)	$\checkmark$
278	Ocular pain (HP:0200026)	$\checkmark$
279	Vitreous floaters (HP:0100832)	$\checkmark$
280	Blindness (HP:0000618)	-
281	Blurred vision (HP:0000622)	-
282	Gaze-evoked nystagmus (HP:0000640)	-
283	Ocular pruritus (HP:0033841)	-
284	Peripheral visual field loss (HP:0007994)	-
285	Photophobia (HP:0000613)	-
286	Red eye (HP:0025337)	-
287	Visual loss (HP:0000572)	-

Table S11. Eye HPO terms that were observed (  $\checkmark$  ) or not (-) in the EHR data.

Covariate	Sig.?
AKI	$\checkmark$
Chronic lung disease	$ \begin{array}{c} \checkmark \\ \checkmark \\$
Congestive heart failure	$\checkmark$
Coronary artery disease	$\checkmark$
Depression	$\checkmark$
Diabetes (complicated)	$\checkmark$
Diabetes (uncomplicated)	$\checkmark$
Heart failure	$\checkmark$
Hypertension	$\checkmark$
Kidney disease	$\checkmark$
Obsesity	$ \begin{array}{c} \checkmark\\ \checkmark\\ \checkmark\\ \checkmark\\ \checkmark\\ \checkmark\\ \checkmark\\ \checkmark \end{array} $
Peripheral vascular disease	$\checkmark$
Systemic corticosteroids	$\checkmark$
At least one vaccine recorded	-
Cardiomyopathies	-
Cerebrovascular disease	-
Dementia	-
Down syndrome	-
Hemiplegia or paraplegia	-
HIV infection	-
Malignant cancer	-
Metastatic solid tumor cancer	-
Mild liver disease	-
Moderate liver disease	-
Multiple sclerosis	-
Myocardial infarction	-
Obstructive sleep apnea	-
Peptic ulcer	-
Psychosis	-
Sickle cell disease	-
Substance abuse	-
Thalassemia	-
Tobacco smoker	-
Tuberculosis	-
Rheumatoligical disease	-

Table S12. Covariates assessed prior to acute COVID-19. The statistically significant covariates are shown in the main manuscript. n.s.: non-significant.  $\checkmark$ : statistically significant with Bonferroni-corrected p < 0.05. Abbreviations: AKI: acute kidney injury. IMV: Invasive mechanical ventilation.

Covariate	Sig.?
AKI	$\checkmark$
IMV	$\checkmark$
COVID regimen corticosteroids	$\checkmark$
Sepsis	$\checkmark$
Vasopressors	$\checkmark$
Remdesivir	$\checkmark$
Death during COVID hospitalization	-
ECMO	-
COVID diagnosis during hospitalization	-

Table S13. Covariates assessed during acute COVID-19. The statistically significant covariates are shown in the main manuscript. n.s.: non-significant.  $\checkmark$ : statistically significant with Bonferroni-corrected p < 0.05. Abbreviations: AKI: acute kidney injury. IMV: Invasive mechanical ventilation.




Figure S1. Determination of optimal k using the elbow method. For patients from data partner 1 (blue) or data partners 2 - 5 (red), patients were clustered with the k-means algorithm using values of k shown on the x-axis. For each value of k, the sum of squared error (SSE) (x  $10^4$ ) of the distance from each patient to the centroid of the patient's cluster (solid lines) and the decrease in SSE (x  $10^4$ ) from the previous k (dotted lines) is shown on the y-axis.

HPO	Cluster 1	Cluster 2	Cluster 3	Cluster 4
Vertigo	28.4%	8.2%	7.7%	18.1%
Hypotension	21.8%	16.0%	1.3%	2.4%
Palpitations	22.6%	2.4%	3.0%	15.5%
Tachycardia	49.4%	17.4%	3.0%	16.0%
Fever	40.6%	19.5%	5.4%	10.8%
Diarrhea	38.3%	15.4%	4.7%	5.2%
Nausea	24.5%	7.2%	3.4%	6.8%
Asthenia	39.5%	18.4%	2.0%	8.4%
Chest pain	49.8%	8.9%	0.0%	49.3%
Fatigue	64.8%	23.5%	4.0%	56.4%
Myalgia	29.1%	3.8%	0.0%	20.2%
Pain	77.8%	19.8%	2.3%	72.7%
Lymphopenia	46.7%	61.8%	2.7%	4.2%
Elevated ALP	25.7%	21.8%	1.3%	1.0%
Elevated ASAT	46.7%	53.6%	0.7%	1.3%
Elevated creatinine	29.1%	38.9%	2.3%	1.8%
Hyperglycemia	77.4%	78.8%	20.5%	26.8%
Hypocalcemia	62.5%	72.4%	1.0%	3.4%
Increased ferritin	18.4%	20.1%	0.0%	0.3%
Thrombocytopenia	30.7%	35.8%	1.7%	1.6%
Abnormality of movement	20.7%	3.8%	7.7%	7.6%
Depression	21.8%	8.9%	8.7%	7.3%
Headache	36.8%	6.5%	14.1%	23.4%
Insomnia	23.0%	8.5%	8.1%	8.7%
Cough	59.8%	25.3%	44.0%	36.7%
Hypoxemia	69.7%	64.5%	17.8%	17.3%

Figure S2. Summary of phenotypic feature distribution in the four clusters. HPO terms are shown if Pearson's chi-squared test on the numbers of patients in each category with the feature was significant with p < 0.00001 and if at least 20% of patients in at least one cluster had the feature. Terms are grouped in categories shown color coded on the left.

HPO	Cluster 1	Cluster 2	Cluster 3	Cluster 4	Cluster 5
Vertigo	27.6%	8.2%	19.1%	19.7%	2.2%
Hypotension	22.4%	16.1%	1.9%	2.6%	1.7%
Palpitations	21.7%	2.5%	3.7%	19.7%	2.2%
Tachycardia	47.6%	17.9%	4.3%	20.7%	3.5%
Fever	39.8%	20.4%	2.5%	12.9%	7.9%
Diarrhea	38.6%	15.8%	9.3%	6.1%	1.3%
Nausea	24.4%	7.9%	7.4%	7.1%	1.3%
Asthenia	40.9%	19.4%	6.2%	6.1%	3.5%
Chest pain	48.4%	9.3%	4.3%	60.5%	0.4%
Fatigue	64.6%	24.4%	25.3%	50.5%	15.7%
Myalgia	29.1%	3.9%	3.1%	23.9%	0.0%
Pain	77.2%	20.1%	14.8%	85.1%	2.6%
Lymphopenia	48.0%	62.7%	5.6%	4.2%	3.5%
Elevated ALP	25.6%	22.2%	1.2%	1.9%	1.7%
Elevated ASAT	48.0%	55.6%	0.6%	1.6%	1.3%
Elevated creatinine	30.3%	40.5%	4.3%	1.3%	1.3%
Hyperglycemia	79.1%	77.8%	16.0%	27.8%	28.8%
Hypocalcemia	63.4%	74.9%	1.2%	4.9%	1.7%
Increased ferritin	18.9%	21.1%	0.0%	0.3%	0.0%
Thrombocytopenia	31.1%	37.3%	4.9%	1.3%	0.4%
Abnormality of movement	20.9%	3.2%	19.1%	6.5%	1.7%
Depression	23.2%	8.2%	26.5%	3.9%	0.0%
Headache	37.4%	6.1%	32.7%	22.0%	5.7%
Insomnia	24.0%	8.6%	7.4%	8.7%	7.9%
Cough	59.1%	24.7%	15.4%	38.8%	59.8%
Hypoxemia	70.5%	64.5%	9.3%	18.8%	25.3%

Figure S3. Summary of phenotypic feature distribution in the five clusters. HPO terms are shown if Pearson's chi-squared test on the numbers of patients in each category with the feature was significant with p < 0.00001 and if at least 20% of patients in at least one cluster had the feature. Terms are grouped in categories shown color coded on the left.